Fraunhofer Institute for Toxicology and Experimental MedicineBiotech Innovation Spotlight: Liquid Biopsy
The conference “Biotech Innovation Spotlight: Liquid Biopsy” will be held as a digital event on November 22, 2022. Dr. Bernhard Polzer from Fraunhofer ITEM will contribute an oral presentation.
BIOSYNTH project: DNA for data storage
Modular high-throughput microplatform for future mass data storage based on synthetic biology
more info© Adobe Stock
Rechengitter für die thermische Simulation mit einer vergrößerten Darstellung des Expositionsgeräts NanoCube. In Gelb sind die Aerosolbereiche, die anderen Bereiche sind entweder Bauteile oder Luftbereiche.
Medical engineering to help assess nanoparticles
Fraunhofer scientists are developing the exposure device NanoCube whose integrated multi-organ chip detects interaction of nanoparticles and lung cells.
more info© Fraunhofer SCAI
Designer cells: novel immune cell platforms for health research
Start of Fraunhofer Attract group headed by Prof. Dr. Nico Lachmann.
more info© MHH, Mania Ackermann
Understanding Cabin Air Quality
The recently launched research project ”Cabin air quality III“ is aimed at assessing long-term effects of contaminants that aircraft passengers and crew members are exposed to on board.
more info© Adobe Stock
FibroPaths®
Therapeutic modulation of organ fibrosis in biochip format – enabling rapid and safe development of antifibrotic drugs
more info© Fraunhofer ITEM, Ralf Mohr
Project RNAuto
Fraunhofer develops automated production technologies for mRNA-based drugs.
more info© Adobe Stock, Ekaterina_1525
Alternatives to animal testing
Fraunhofer on the way to predictive models of the future – the lecture series of the CIMD competence platform features monthly talks.
more info© Fraunhofer ITEM, Ralf Mohr
Medical research on SARS-CoV-2
With our decades of experience in infection and airway research, drug development, biomedical engineering, and in the field of chemical risk assessment, we are meanwhile involved in numerous projects to fight the COVID-19 pandemic.
more info© Fraunhofer
High-Performance Center
The High-Performance Center Medical and Pharmaceutical Engineering, launched in March, creates a platform for research and the transfer of innovations into patient care.
more info© Fraunhofer IMTE, Dr. Thomas Friedrich
About Fraunhofer ITEM
The Fraunhofer Institute for Toxicology and Experimental Medicine ITEM is one of 76 institutes and research institutions of the Fraunhofer-Gesellschaft, the world’s leading applied research organization. Protecting man from health hazards in our industrialized world and contributing to the development of novel therapeutic approaches are the aims Fraunhofer ITEM is pursuing with its contract research. With a focus on cardiopulmonary research, our R&D portfolio includes three business areas: Drug Development, Chemical Safety and Translational Biomedical Engineering. In addition, our scientists in Regensburg do research in the field of personalized tumor therapy.
With a staff of around 450 at its locations in Hannover, Braunschweig and Regensburg, the institute cooperates with industry, service providers, and public authorities in projects that drive economic development and serve the wider benefit of society.